Company | Imperial Brands CEO: Expects double-digit NGP growth over the next five years; ZONE nicotine pouches reach ~3% share in the U.S.

Sep.12.2025
Company | Imperial Brands CEO: Expects double-digit NGP growth over the next five years; ZONE nicotine pouches reach ~3% share in the U.S.
At the Barclays Global Consumer Staples Conference, the CEO of Imperial Brands outlined the company’s 2025–2030 strategy and direction for its Next-Generation Products (NGP). He said the NGP business has been “reset,” delivering double-digit growth over the past two years, with the aim of sustaining this pace for the next five years. In response to disposable-vape bans in the UK and France, the company has completed a pivot to rechargeable pod systems, doubling its UK market share and surpassing

Key Points

 

  • Growth target: Imperial aims to sustain double-digit net revenue growth in Next-Generation Products (NGP) for the next five years; the company says it has delivered double-digit growth over the past two years with share gains across its three NGP categories.

 

  • Go-to-market: Primarily organic growth, supplemented by small bolt-on M&A; entry focus on markets where the category is established and route-to-market is in place.

 

  • UK/France shift: Following disposable vape bans, the business has pivoted to rechargeable pod systems; UK vapor share has doubled in the past 12 months and exceeded 10% in H1.

 

  • U.S. oral nicotine: ZONE, launched in Feb 2024, has reached about 3% market share in ~18 months; a more moist pouch option has been introduced, with emphasis on regulatory compliance.

 

  • Portfolio mix: NGP revenue is roughly 75% vapor / 25% oral nicotine; CEO Stefan Bomhard says new launches will be prioritized only once categories reach sufficient scale (e.g., delaying pouches in the UK until the market matures).

 


 

2Firsts, September 12, 2025 — In a fireside chat at the Barclays Global Consumer Staples Conference, Imperial Brands CEO Stefan Bomhard outlined the company’s 2025–2030 strategy and direction for Next-Generation Products (NGP). He said Imperial has “reset” its NGP business over the past five years, delivering double-digit growth in the last two and gaining share across its three NGP categories. The group is targeting another five years of double-digit NGP growth.

 

On market selection and expansion, Bomhard said Imperial prioritizes countries where the category is already established and distribution is in place, launching differentiated propositions against clear consumer needs. He reiterated Imperial’s positioning as the world’s fourth-largest tobacco company.

 

Addressing policy shifts in Europe, he noted that after the disposable-vape bans in the UK and France, Imperial transitioned its offers to rechargeable pod systems. Over the past 12 months, the company’s UK vapor share has doubled, and in the first half it surpassed 10% for the first time. Pods will remain the core of its UK and French supply strategy.

 

In the United States, the ZONE nicotine-pouch brand, launched in February 2024, has reached around 3% market share in roughly 18 months. Imperial has added a more moist pouch option and stressed adherence to regulatory processes. As for introducing pouches in the UK, Bomhard described the category as “small and fragmented,” indicating Imperial will wait for the market to stabilize before entering.

 

Imperial’s NGP mix is about 75% vapor and 25% oral nicotine. The company will expand in a disciplined manner—largely organically—with small acquisitions considered only as supplements, keeping a tight focus on consumer insight and execution in the trade.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
R.J. Reynolds Vapor Company has introduced Vuse Pro prefilled pods in Peach, Berry, Watermelon and Fresh Mint in selected U.S. states. Vuse’s U.S. website says the pods are intended for use with existing Vuse Alto devices. Each contains 2.0 mL of e-liquid at 5.0% nicotine by weight, uses nicotine salts and is offered in two- and four-pod packs. Reynolds said the rollout includes mandatory ID scanning for every purchase, purchase limits, stronger retailer-accountability requirements and strict age-restricted marketing standards. The four pods have not received marketing authorization from the U.S. Food and Drug Administration.
Sep.10
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19